Mgr. Bc. Petra Májková
Analyst, Institute of Biostatistics and Analyses
Correspondence Address:
Kamenice 753/5, 625 00 Brno
E‑mail: |
---|
Total number of publications: 21
2023
-
Clinical characteristics and mortality in all Czech patients after pacemaker implantation in the last decade
Frontiers in Cardiovascular Medicine, year: 2023, volume: 10, edition: December 2023, DOI
2020
-
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment - prospective data from the Czech TULUNG registry
Year: 2020, type: Conference abstract
2019
-
Charakteristika pacientů s NSCLC léčených inhibitory tyrozinkiázy (TKI) první a druhé generace po stanovení diagnózy v ČR
Year: 2019, type: Conference abstract
-
Tyrosine-kinase inhibitors (TKI) in first-line treatment of 470 patients with non-small cell lung cancer (NSCLC) from the Czech Republic
Year: 2019, type: Conference abstract
2017
-
Locally advanced breast cancer in elderly patients
Biomedical Papers of the Faculty of Medicine of Palacký University, Olomouc, Czech Republic, year: 2017, volume: 161, edition: 2, DOI
2014
-
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
Haematologica/the hematology journal, year: 2014, volume: 99, edition: 2, DOI
2013
-
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Clinical lymphoma, myeloma & leukemia, year: 2013, volume: 13, edition: 2, DOI
2012
-
Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial
Leukemia & Lymphoma, year: 2012, volume: 53, edition: 5, DOI
2011
-
Association Study of Selected Genetic Polymorphisms and Occurrence of Venous Thromboembolism in Patients With Multiple Myeloma Who Were Treated With Thalidomide
Clinical Lymphoma, Myeloma & Leukemia, year: 2011, volume: 11, edition: 5, DOI
-
Better treatment response is associated with lenalidomide 25 mg once-daily vs. 25 mg every-other-day in relapsed/refractory multiple myeloma
Year: 2011, type: Conference abstract